Get the Stockscreener App
18.95
4.92%
-0.98
After Hours:
18.95
Vera Therapeutics Inc stock is traded at $18.95, with a volume of 2.15M.
It is down -4.92% in the last 24 hours and down -21.04% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$19.93
Open:
$19.68
24h Volume:
2.15M
Relative Volume:
2.20
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-8.5747
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-3.51%
1M Performance:
-21.04%
6M Performance:
-61.91%
1Y Performance:
-48.71%
1-Day Range:
$18.79
$19.86
1-Week Range:
$18.76
$20.21
52-Week Range:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
18.95 | 1.25B | 0 | -107.85M | -106.82M | -2.21 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Ameriprise Financial Inc. Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Millennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of “Buy” by Analysts - Defense World
Cantor Fitzgerald maintains Vera Therapeutics at Overweight By Investing.com - Investing.com Canada
Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential - TipRanks
BNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics Holds 2025 Annual Stockholder Meeting - TipRanks
Dimensional Fund Advisors LP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug (NASDAQ:VERA) - Seeking Alpha
How To Trade (VERA) - news.stocktradersdaily.com
Research Analysts Set Expectations for VERA FY2025 Earnings - Defense World
Northern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail
FY2025 EPS Estimates for VERA Decreased by Cantor Fitzgerald - Defense World
Q2 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
Q2 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
Hsbc Holdings PLC Takes $264,000 Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - The AM Reporter
Cantor Fitzgerald Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $100.00 - Defense World
Wedbush Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $26.00 - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What is Wedbush’s Estimate for VERA Q1 Earnings? - Defense World
Analysts Set Expectations for VERA Q2 Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail
Analysts Issue Forecasts for VERA Q1 Earnings - Defense World
Decoding Vera Therapeutics Inc (VERA): A Strategic SWOT Insight - GuruFocus
Ratios Reveal: Breaking Down Vera Therapeutics Inc (VERA)’s Financial Health - DWinneX
Vera Therapeutics (VERA) Price Target Adjusted by Cantor Fitzgerald | VERA Stock News - GuruFocus
Vera Therapeutics Advances Atacicept in Key Trials - TipRanks
Vera Therapeutics shares fall as Q1 loss exceeds estimates By Investing.com - Investing.com India
Vera Therapeutics shares fall as Q1 loss exceeds estimates - Investing.com Australia
Medtronic gains after boosting full-year guidance By Investing.com - Investing.com India
Vera Therapeutics reports Q1 EPS (81c), consensus (78c) - TipRanks
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Vera Therapeutics (VERA) - The Globe and Mail
Vera Therapeutics' Q1 Net Loss Widens - marketscreener.com
Vera Therapeutics (VERA) Awaits Key Trial Results for Atacicept - GuruFocus
Vera Therapeutics (VERA) Awaits Key Trial Results for Atacicept | VERA Stock News - GuruFocus
Earnings Flash (VERA) Vera Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.75 Loss - marketscreener.com
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
BRIEF-Vera Therapeutics Q1 EPS USD -0.81 Vs. IBES Estimate USD -0.74 - TradingView
Vera Therapeutics (NASDAQ:VERA) Coverage Initiated by Analysts at HC Wainwright - Defense World
Vera Therapeutics (VERA) Gains Positive Outlook with Buy Rating - GuruFocus
Vera Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
Vera Therapeutics (VERA) Receives New Buy Rating from HC Wainwri - GuruFocus
(VERA) On The My Stocks Page - news.stocktradersdaily.com
Invesco Ltd. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Vera Therapeutics Inc (VERA) - Sete News
Vera Therapeutics Inc (VERA) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Insider’s View: Deciphering Vera Therapeutics Inc (VERA)’s Financial Health Through Ratios - DWinneX
Vera Therapeutics Inc (VERA)’s stock performance: a year in review - uspostnews.com
Vera Therapeutics (VERA) Expected to Announce Earnings on Thursday - Defense World
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):